Brokerages Set Insulet Corporation (NASDAQ:PODD) Target Price at $379.10

Shares of Insulet Corporation (NASDAQ:PODD) have received a consensus recommendation of “Moderate Buy” from the twenty-four research firms that are currently covering the company, MarketBeat.com reports. Four research analysts have rated the stock with a hold recommendation and twenty have assigned a buy recommendation to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $375.0476.

A number of brokerages have recently commented on PODD. Wells Fargo & Company lifted their price objective on shares of Insulet from $350.00 to $360.00 and gave the company an “overweight” rating in a research report on Friday, November 7th. Canaccord Genuity Group boosted their price target on Insulet from $432.00 to $450.00 and gave the company a “buy” rating in a research note on Wednesday, December 17th. Barclays boosted their target price on shares of Insulet from $300.00 to $301.00 and gave the company an “equal weight” rating in a research report on Wednesday, November 5th. Wolfe Research boosted their price target on Insulet from $350.00 to $375.00 and gave the stock an “outperform” rating in a report on Friday, November 7th. Finally, UBS Group reiterated a “buy” rating on shares of Insulet in a research report on Thursday, December 18th.

Insulet Price Performance

NASDAQ PODD opened at $255.10 on Friday. The company has a debt-to-equity ratio of 0.68, a quick ratio of 2.18 and a current ratio of 2.87. The stock has a market cap of $17.95 billion, a price-to-earnings ratio of 73.94, a PEG ratio of 1.44 and a beta of 1.40. The business has a 50 day simple moving average of $293.06 and a 200 day simple moving average of $309.24. Insulet has a 52-week low of $230.05 and a 52-week high of $354.88.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $1.24 EPS for the quarter, topping analysts’ consensus estimates of $1.13 by $0.11. The business had revenue of $521.70 million for the quarter, compared to analyst estimates of $678.70 million. Insulet had a net margin of 9.76% and a return on equity of 24.36%. The firm’s quarterly revenue was up 29.9% on a year-over-year basis. During the same period last year, the business posted $1.08 earnings per share. Analysts anticipate that Insulet will post 3.92 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Sage Mountain Advisors LLC increased its stake in shares of Insulet by 4.6% during the 3rd quarter. Sage Mountain Advisors LLC now owns 743 shares of the medical instruments supplier’s stock worth $229,000 after purchasing an additional 33 shares during the last quarter. Glenmede Investment Management LP lifted its holdings in shares of Insulet by 1.6% during the 3rd quarter. Glenmede Investment Management LP now owns 2,292 shares of the medical instruments supplier’s stock worth $708,000 after acquiring an additional 35 shares during the last quarter. Curi Capital LLC raised its stake in shares of Insulet by 0.8% during the second quarter. Curi Capital LLC now owns 4,346 shares of the medical instruments supplier’s stock worth $1,365,000 after acquiring an additional 36 shares in the last quarter. WINTON GROUP Ltd lifted its stake in Insulet by 0.9% in the third quarter. WINTON GROUP Ltd now owns 4,086 shares of the medical instruments supplier’s stock worth $1,261,000 after purchasing an additional 37 shares during the last quarter. Finally, Evelyn Partners Investment Management Services Ltd increased its holdings in shares of Insulet by 28.7% in the second quarter. Evelyn Partners Investment Management Services Ltd now owns 175 shares of the medical instruments supplier’s stock worth $55,000 after buying an additional 39 shares during the period.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.